Monogram Acquisition Bolsters LabCorp's PGx Test Portfolio, Companion Dx Know-how | GenomeWeb

By Turna Ray

LabCorp this week announced plans to acquire Monogram Biosciences for $107 million — a deal that will add to its portfolio several oncology pharmacogenomic tests and a companion diagnostic that is often held up as one of the best examples of drug/diagnostic co-development.

In a statement, LabCorp said it plans to acquire all of the outstanding shares of Monogram for $4.55 per share for an equity value of approximately $106.7 million, or $155 million including the assumption of debt.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.